FDA批準皮下注射藥阿必魯泰(Tanzeum)用於2型糖尿病

FDA批準阿必魯泰用於二型糖尿病: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm

葛蘭素史克(GSK,GlaxoSmithKline)研發的阿必魯泰(Tanzeum (albiglutide) )是一種GLP-1(glucagon-like peptide-1,胰高血糖素樣肽-1)受體激動劑，患者每周一次接受皮下注射。需輔以飲食和運動。Tanzeum的獲批是基於全麵III期Harmony項目的數據，包含8項試驗，涉及超過5000例患者，其中有超過2000例患者接受了 Tanzeum 的治療，證實藥物有助顯著改善糖化血紅蛋白(HbA1c level)。但這個藥不適用於一型糖尿病。

......

Tanzeum is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. The drug’s safety and effectiveness were evaluated in eight clinical trials involving more than 2,000 patients with type 2 diabetes. Patients participating in the trials showed an improvement in their HbA1c level (hemoglobin A1c or glycosylated hemoglobin, a measure of blood sugar control).

Tanzeum has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies, including metformin, glimepiride, pioglitazone, and insulin. Tanzeum should not be used to treat people with type 1 diabetes; those who have increased ketones in their blood or urine (diabetic ketoacidosis); or as first-line therapy for patients who can’t be managed with diet and exercise.

Tanzeum has a Boxed Warning to warn that tumors of the thyroid gland (thyroid C-cell tumors) have been observed in rodent studies with some GLP-1 receptor agonists, but that it is unknown whether Tanzeum causes thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC), in humans. Tanzeum should not be used in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (a disease where patients have tumors in more than one gland in their body and that predisposes them to MTC).
......



各國牛奶的消耗量。中國的人均牛奶消耗量好低，less than 37.37，比日本的低。
via chart*****in.com